Fulgent Genetics, Inc. (FLGT) Stock Analysis and Metrics

Fulgent Genetics

NASDAQ: FLGT

$20.42 ▼ -0.13 (-0.63%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap642.94 Mn

P/E-8.71

P/S2.71

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)32.10 Mn

Revenue Growth (1y) (Qtr)-3.16

Add ratio to table…

About

Fulgent Genetics, Inc. is a technology based company that operates a laboratory services business and a therapeutic development business. The firm was founded in 2011 with the founding principles of flexibility and affordability in genetic testing. It seeks to offer the broadest possible menu of diagnostic tests while keeping costs low for patients and providers. The laboratory services division performs anatomic pathology and molecular diagnostics using a variety of platforms. The therapeutic development division is focused on creating new drug formulations through a proprietary nanoencapsulation technology. The company envisions evolving from a pure diagnostics provider into a fully integrated precision medicine enterprise. Its laboratories hold CLIA certification in several states and are accredited by the College of American Pathologists. The firm invests in digital pathology tools that use artificial intelligence to assist pathologists in reading slides.

Revenue is generated mainly from fees charged for laboratory tests performed for hospitals reference labs and other institutional clients. The firm bills these clients directly and receives payment based on negotiated rates or fee schedules. A portion of revenue comes from patients who pay for tests out of pocket after ordering through the consumer facing platform. The company also provides test development and licensing services to pharmaceutical and biotech firms which generate additional income. Although the therapeutic development segment has not yet commercialized a product it may earn future revenue from licensing agreements royalties or milestone payments once its drug candidates advance through clinical trials. The firm continues to expand its test menu and increase test volume to drive top line growth.

The company operates through the following segments: Laboratory Services and Therapeutic Development.

• Laboratory Services provides an extensive anatomic pathology menu that includes gastrointestinal dermatopathology urologic breast neuropathology and hematopathology examinations. The segment offers precision diagnostics such as next generation sequencing panels for rare disease hereditary cancer reproductive health and many other indications. Additional testing capabilities encompass flow cytometry cytogenetic analysis fluorescence in situ hybridization immunohistochemistry molecular genetics and specialized consultations in hematopathology and surgical pathology. The division has built a digital pathology platform that uses artificial intelligence to digitize slides and support image analysis for faster diagnosis. An in house image management system was created to handle high case volumes and to enable the integration of AI tools into the workflow. The company’s proprietary technology platform features custom gene probes data suppression algorithms and a laboratory information management system that together allow rapid test development and lower cost per test. Laboratories operate under CLIA certification in California Texas Georgia Massachusetts Arizona and other locations ensuring compliance with federal quality standards.

• Therapeutic Development concentrates on a nano drug delivery platform that encapsulates active pharmaceutical ingredients within tiny carriers to improve solubility and control release. The platform’s materials are soluble in water and in various organic solvents and they can be hot mixed with active pharmaceutical ingredients to form stable formulations. This flexibility enables the creation of both intravenous and oral dosage forms aimed at enhancing pharmacokinetic profiles and reducing toxicity. The lead candidate FID 007 is a paclitaxel nanoencapsulation currently undergoing phase one and phase two clinical trials for head and neck and other solid tumor indications. Another candidate FID 022 contains the SN38 payload and is being evaluated in a phase one study for solid tumor safety and tolerability. The division is also advancing antibody drug conjugate research using a novel linker and payload system designed to increase efficacy against multiple tumor antigens. Preclinical data suggest that these constructs demonstrate favorable activity with manageable safety signals. The ultimate goal is to bring new cancer therapies to market that address unmet medical needs and improve patient outcomes.

The firm operates in a highly competitive diagnostic testing environment where dozens of laboratories offer similar genetic and pathology services. Notable competitors include Ambry Genetics Baylor Genetics Caris Life Sciences Exact Sciences Foundation Medicine GeneDx Labcorp Myriad Genetics Natera NeoGenomics Quest Diagnostics and Tempus AI. In the therapeutic arena the company faces large pharmaceutical corporations as well as other nanotechnology based drug delivery developers. Fulgent Genetics differentiates itself through a proprietary test development pipeline that can introduce new assays quickly and at low cost. Its artificial intelligence driven digital pathology system improves workflow efficiency and diagnostic accuracy. The company’s CLIA certified laboratories are geographically diversified which provides broad access to institutional customers. Intellectual property protection is strong with numerous patents covering the nanoencapsulation platform and related drug formulations. While larger rivals possess deeper financial resources and broader brand recognition Fulgent Genetics relies on its agility and specialized technology to carve out a niche in the market.

The company serves a mixed customer base that includes institutional clients such as hospitals medical laboratories reference labs and large corporations that order tests for their patients. Insurance companies and government payors also contribute to revenue through reimbursement for covered tests. A segment of patients pays directly for services after receiving a test order from their physician. The firm reports that one specific customer accounted for roughly twenty two percent of total revenue in both 2024 and 2025 highlighting a concentration risk. The remaining business is spread across many different payors and provider types reducing reliance on any single source. The organization continues to pursue growth by expanding its test offerings and strengthening its sales and marketing efforts across all customer segments.

Investment Thesis

▲ Bull case

The partnership with Foundation Medicine to launch FoundationOne PGx creates a clear near‑term revenue driver that leverages Fulgent’s existing high‑throughput sequencing platform and rapid turnaround capabilities. This test targets the growing prophylactic pharmacogenomics market spurred by updated ASCO and NCCN guidelines that now recommend routine DPYD genotyping before fluoropyrimidine therapy. By offering a comprehensive oncology‑relevant panel Fulgent can capture a sizable share of the PGx spend that is shifting from discretionary to routine ordering. The collaboration also strengthens Fulgent’s positioning in precision oncology without requiring significant additional capital investment.
Phase II data for FID‑007 presented at ASCO demonstrate meaningful anticancer activity and a favorable tolerability profile when combined with cetuximab in recurrent metastatic head and neck squamous cell carcinoma. This disease area currently has limited effective options with historical objective response rates below twenty% and progression‑free survival under four months. The positive interim results de‑risk the binary outcome of the drug candidate and increase the likelihood of a successful Phase III registration trial. Consequently the asset holds upside optionality through potential partnership licensing or an accelerated regulatory path that the market may not be fully valuing.
The integration of Illumina’s TruPath Genome technology into Fulgent’s whole genome test eliminates the need for sequential workflows by delivering long‑range genomic insights on existing short‑read infrastructure. This advancement should increase diagnostic yield for rare disease patients while reducing turnaround time and per‑test cost. As the test scales, the improved efficiency can support margin expansion and reinforce Fulgent’s competitive differentiation in a crowded market. The development represents a structural shift toward more comprehensive genomic reporting that aligns with evolving clinical demand.
Investments in AI‑driven digital pathology, exemplified by the auto‑rotation tool for dermatopathology slides, are already improving workflow efficiency and diagnostic accuracy. By standardizing slide orientation the tool reduces pathologist cognitive load and the time spent adjusting images, which can lead to faster turnaround and fewer interpretation errors. These efficiency gains have the potential to increase test volume and improve reimbursement rates without proportional increases in labor costs. Although management highlighted the initiative they did not quantify its financial impact in forward guidance, suggesting an underappreciated source of operating leverage.
The acquisition of Bako Diagnostics and StrataDx more than doubles Fulgent’s anatomic pathology sales force and adds an established customer base expected to contribute roughly fifty‑three million dollars to revenue in the second half of 2026. This contribution is intended to offset the decline from the largest customer’s in‑house transition and improve overall customer concentration, a factor reinforced by the company’s reiterated guidance that no single client will exceed ten% of total revenue. Successful integration could therefore de‑risk the revenue base and provide a platform for cross‑selling pathology and genetic testing services. The strategic fit between the acquired businesses and Fulgent’s existing platform enhances the likelihood of realizing synergies.

The partnership with Foundation Medicine to launch FoundationOne PGx creates a clear near‑term revenue driver that leverages Fulgent’s existing high‑throughput sequencing platform and rapid turnaround capabilities. This test targets the growing prophylactic pharmacogenomics market spurred by updated ASCO and NCCN guidelines that now recommend routine DPYD genotyping before fluoropyrimidine therapy. By offering a comprehensive oncology‑relevant panel Fulgent can capture a sizable share of the PGx spend that is shifting from discretionary to routine ordering. The collaboration also strengthens Fulgent’s positioning in precision oncology without requiring significant additional capital investment.
Phase II data for FID‑007 presented at ASCO demonstrate meaningful anticancer activity and a favorable tolerability profile when combined with cetuximab in recurrent metastatic head and neck squamous cell carcinoma. This disease area currently has limited effective options with historical objective response rates below twenty% and progression‑free survival under four months. The positive interim results de‑risk the binary outcome of the drug candidate and increase the likelihood of a successful Phase III registration trial. Consequently the asset holds upside optionality through potential partnership licensing or an accelerated regulatory path that the market may not be fully valuing.
The integration of Illumina’s TruPath Genome technology into Fulgent’s whole genome test eliminates the need for sequential workflows by delivering long‑range genomic insights on existing short‑read infrastructure. This advancement should increase diagnostic yield for rare disease patients while reducing turnaround time and per‑test cost. As the test scales, the improved efficiency can support margin expansion and reinforce Fulgent’s competitive differentiation in a crowded market. The development represents a structural shift toward more comprehensive genomic reporting that aligns with evolving clinical demand.
Investments in AI‑driven digital pathology, exemplified by the auto‑rotation tool for dermatopathology slides, are already improving workflow efficiency and diagnostic accuracy. By standardizing slide orientation the tool reduces pathologist cognitive load and the time spent adjusting images, which can lead to faster turnaround and fewer interpretation errors. These efficiency gains have the potential to increase test volume and improve reimbursement rates without proportional increases in labor costs. Although management highlighted the initiative they did not quantify its financial impact in forward guidance, suggesting an underappreciated source of operating leverage.
The acquisition of Bako Diagnostics and StrataDx more than doubles Fulgent’s anatomic pathology sales force and adds an established customer base expected to contribute roughly fifty‑three million dollars to revenue in the second half of 2026. This contribution is intended to offset the decline from the largest customer’s in‑house transition and improve overall customer concentration, a factor reinforced by the company’s reiterated guidance that no single client will exceed ten% of total revenue. Successful integration could therefore de‑risk the revenue base and provide a platform for cross‑selling pathology and genetic testing services. The strategic fit between the acquired businesses and Fulgent’s existing platform enhances the likelihood of realizing synergies.

▼ Bear case

Despite the company’s optimism the business remains materially exposed to a single large customer whose testing volumes are shifting in‑house, and while the Bako and StrataDx acquisitions are expected to mitigate this loss, any delay in integration or lower‑than‑expected contribution could leave a persistent revenue shortfall. The first quarter already showed a noticeable sequential decline driven by this customer, and historical lumpiness in the segment suggests that revenue recovery may not be smooth. If the offset from the acquired businesses falls short of the projected fifty‑three million dollars the overall top line could struggle to meet the reiterated three hundred fifty million dollar guidance. This concentration risk continues to represent a material headwind that investors may be underestimating.
Gross margin compression in the first quarter, with GAAP gross margin at thirty point two% and non‑GAAP at thirty‑two point three%, reflects fixed cost deleverage on a lower revenue base, and while management anticipates normalization as the claims backlog clears there is no guarantee that revenue will rebound quickly enough to restore margins to the targeted thirty‑nine% for the full year. Prolonged volume weakness could keep operating leverage suppressed and prevent the anticipated margin expansion later in the year. The reliance on seasonal factors and weather related disruptions further adds uncertainty to the timing of any margin recovery.
The biopharma services segment continues to exhibit pronounced lumpiness due to its dependence on large transactions with long sales cycles, meaning quarterly results can swing sharply based on the timing of a few contracts. Although management expects steady second‑half growth, the pipeline of partnership opportunities may not materialize as anticipated, leaving earnings exposed to volatility that is not fully captured in smoothed guidance. This inherent unpredictability makes it difficult to forecast consistent profitability from the segment and raises the risk of periodic shortfalls that could affect overall operating performance.
Integration risks associated with the Bako Diagnostics and StrataDx acquisitions, including cultural alignment cross‑training of the expanded sales force and potential redundancies, could delay the realization of the projected fifty‑three million dollar revenue contribution and increase operating expenses beyond the current flat non‑GAAP outlook. The first quarter already showed elevated acquisition related costs and severance, and if integration challenges persist these expenses may recur or even rise, eroding the anticipated benefits. The success of the cross‑selling strategy hinges on effective execution, and any missteps could diminish the expected synergies and weigh on profitability.
Management’s decision to decline comment on the CMS CRUSH initiative during the Q&A creates an information gap regarding a potential regulatory or reimbursement headwind that could affect utilization of genetic testing services. Without visibility into how this initiative might alter payer policies or testing guidelines, investors may be underestimating a possible adverse shift that could erode test volumes across multiple product lines. The lack of discussion suggests either uncertainty or a desire to avoid highlighting a risk, both of which warrant caution when assessing forward looking assumptions.

Despite the company’s optimism the business remains materially exposed to a single large customer whose testing volumes are shifting in‑house, and while the Bako and StrataDx acquisitions are expected to mitigate this loss, any delay in integration or lower‑than‑expected contribution could leave a persistent revenue shortfall. The first quarter already showed a noticeable sequential decline driven by this customer, and historical lumpiness in the segment suggests that revenue recovery may not be smooth. If the offset from the acquired businesses falls short of the projected fifty‑three million dollars the overall top line could struggle to meet the reiterated three hundred fifty million dollar guidance. This concentration risk continues to represent a material headwind that investors may be underestimating.
Gross margin compression in the first quarter, with GAAP gross margin at thirty point two% and non‑GAAP at thirty‑two point three%, reflects fixed cost deleverage on a lower revenue base, and while management anticipates normalization as the claims backlog clears there is no guarantee that revenue will rebound quickly enough to restore margins to the targeted thirty‑nine% for the full year. Prolonged volume weakness could keep operating leverage suppressed and prevent the anticipated margin expansion later in the year. The reliance on seasonal factors and weather related disruptions further adds uncertainty to the timing of any margin recovery.
The biopharma services segment continues to exhibit pronounced lumpiness due to its dependence on large transactions with long sales cycles, meaning quarterly results can swing sharply based on the timing of a few contracts. Although management expects steady second‑half growth, the pipeline of partnership opportunities may not materialize as anticipated, leaving earnings exposed to volatility that is not fully captured in smoothed guidance. This inherent unpredictability makes it difficult to forecast consistent profitability from the segment and raises the risk of periodic shortfalls that could affect overall operating performance.
Integration risks associated with the Bako Diagnostics and StrataDx acquisitions, including cultural alignment cross‑training of the expanded sales force and potential redundancies, could delay the realization of the projected fifty‑three million dollar revenue contribution and increase operating expenses beyond the current flat non‑GAAP outlook. The first quarter already showed elevated acquisition related costs and severance, and if integration challenges persist these expenses may recur or even rise, eroding the anticipated benefits. The success of the cross‑selling strategy hinges on effective execution, and any missteps could diminish the expected synergies and weigh on profitability.
Management’s decision to decline comment on the CMS CRUSH initiative during the Q&A creates an information gap regarding a potential regulatory or reimbursement headwind that could affect utilization of genetic testing services. Without visibility into how this initiative might alter payer policies or testing guidelines, investors may be underestimating a possible adverse shift that could erode test volumes across multiple product lines. The lack of discussion suggests either uncertainty or a desire to avoid highlighting a risk, both of which warrant caution when assessing forward looking assumptions.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password